JP2010505809A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505809A5
JP2010505809A5 JP2009530956A JP2009530956A JP2010505809A5 JP 2010505809 A5 JP2010505809 A5 JP 2010505809A5 JP 2009530956 A JP2009530956 A JP 2009530956A JP 2009530956 A JP2009530956 A JP 2009530956A JP 2010505809 A5 JP2010505809 A5 JP 2010505809A5
Authority
JP
Japan
Prior art keywords
methyl
triazol
ethoxy
isoxazol
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009530956A
Other languages
Japanese (ja)
Other versions
JP2010505809A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/002784 external-priority patent/WO2008041075A1/en
Publication of JP2010505809A publication Critical patent/JP2010505809A/en
Publication of JP2010505809A5 publication Critical patent/JP2010505809A5/ja
Pending legal-status Critical Current

Links

Claims (20)

式（Ｉ）：
Figure 2010505809
 ［式中、
R1は、メチル、ハロゲン及びシアノからなる群より選択され;
R2は、水素及びフルオロからなる群より選択され;
R3は、水素及びC1−C3アルキルからなる群より選択され;
R4は、水素及びC1−C3アルキルからなる群より選択され;
R5は、C1−C3アルキル及びシクロプロピルからなる群より選択され;
Ｘは、
Figure 2010505809
 からなる群より選択され、そしてＺは、
Figure 2010505809
 からなる群より選択され、ここで
R6は、水素、C1−C3アルキル、C1−C3ハロアルキル、C1−C3アルコキシ、C1−C3ハロアルコキシ及びハロゲンからなる群より選択され;
R7は、水素、C1−C3アルキル、C1−C3ハロアルキル、C1−C3アルコキシ、C1−C3ハロアルコキシ及びハロゲンからなる群より選択される］
の化合物又はその薬学的に許容しうる塩、水和物、アイソフォーム、互変異性体若しくは鏡像異性体。 Formula (I):
Figure 2010505809
 [Where:
R 1 is selected from the group consisting of methyl, halogen and cyano;
R 2 is selected from the group consisting of hydrogen and fluoro;
R 3 is selected from the group consisting of hydrogen and C 1 -C 3 alkyl;
R 4 is selected from the group consisting of hydrogen and C 1 -C 3 alkyl;
R 5 is selected from the group consisting of C 1 -C 3 alkyl and cyclopropyl;
X is
Figure 2010505809
 And Z is selected from the group consisting of
Figure 2010505809
 Selected from the group consisting of
R 6 is selected from the group consisting of hydrogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, and halogen;
R 7 is selected from the group consisting of hydrogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy and halogen]
Or a pharmaceutically acceptable salt, hydrate, isoform, tautomer or enantiomer thereof. Ｚが、
Figure 2010505809
 からなる群より選択される、請求項１に記載の化合物。 Z is
Figure 2010505809
 2. The compound of claim 1 selected from the group consisting of: R3がC1−C3アルキルであり、R4が水素である、請求項２に記載の化合物。 The compound of claim 2, wherein R 3 is C 1 -C 3 alkyl and R 4 is hydrogen. R3がC1−C3アルキルであり、R4がC1−C3アルキルである、請求項２に記載の化合物。 The compound of claim 2, wherein R 3 is C 1 -C 3 alkyl and R 4 is C 1 -C 3 alkyl. R5がメチルである、請求項１〜４のいずれか１項に記載の化合物。 The compound according to any one of claims 1 to 4, wherein R 5 is methyl. R1がクロロである、請求項１〜５のいずれか１項に記載の化合物。 R 1 is chloro A compound according to any one of claims 1 to 5. R2が水素である、請求項１〜６のいずれか１項に記載の化合物。 R 2 is hydrogen A compound according to any one of claims 1-6. R5がメチルである、請求項１〜７のいずれか１項に記載の化合物。 R 5 is methyl, A compound according to any one of claims 1 to 7. R6が水素である、請求項１〜８のいずれか１項に記載の化合物。 R 6 is hydrogen, A compound according to any one of claims 1-8. R6がC1−C3アルキルである、請求項１〜８のいずれか１項に記載の化合物。 R 6 is C 1 -C 3 alkyl, A compound according to any one of claims 1 to 8. R7が水素である、請求項１〜１０のいずれか１項に記載の化合物。 R 7 is hydrogen, A compound according to any one of claims 1 to 10. R7がC1−C3アルキルである、請求項１〜１０のいずれか１項に記載の化合物。 R 7 is C 1 -C 3 alkyl, A compound according to any one of claims 1 to 10. 4−(5−｛(1R)−1−[5−(3−クロロフェニル)イソオキサゾール−3−イル]エトキシ｝
−4−メチル−4H−1,2,4−トリアゾール−3−イル)−1−メチルピリジン−2(1H)−オン
4−(5−｛(1R)−1−[5−(3−クロロフェニル)−1,2,4−オキサジアゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)−1−メチルピリジン−2(1H)−オン;
4−(5−｛1−[5−(3−クロロフェニル)イソオキサゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリジン−2(1H)−オン;
4−(5−｛[5−(3−クロロフェニル)イソオキサゾール−3−イル]メトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリジン−2(1H)−オン;
4−(5−｛(1R)−1−[5−(3−クロロフェニル)イソオキサゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリジン−2(1H)−オン;
4−(5−｛(1R)−1−[5−(3−クロロフェニル)−1,2,4−オキサジアゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリジン−2(1H)−オン;
4−(5−｛(1R)−1−[2−(3−クロロフェニル)−2H−テトラゾール−5−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリジン−2(1H)−オン;
5−(5−｛(1R)−1−[2−(3−クロロフェニル)−2H−テトラゾール−5−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリダジン−3(2H)−オン;
5−(5−｛(1R)−1−[5−(3−クロロフェニル)−1,2,4−オキサジアゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリダジン−3(2H)−オン;
5−(5−｛(1R)−1−[5−(3−クロロフェニル)イソオキサゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)ピリダジン−3(2H)−オン;
5−(4−メチル−5−｛(1R)−1−[2−(3−メチルフェニル)−2H−テトラゾール−5−イル]エトキシ｝−4H−1,2,4−トリアゾール−3−イル)ピリダジン−3(2H)−オン;及び
5−(4−メチル−5−｛(1R)−1−[5−(3−メチルフェニル)イソオキサゾール−3−イル]エトキシ｝−4H−1,2,4−トリアゾール−3−イル)ピリダジン−3(2H)−オン、
からなる群より選択される化合物。 4- (5-{(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy}
-4-methyl-4H-1,2,4-triazol-3-yl) -1-methylpyridin-2 (1H) -one
4- (5-{(1R) -1- [5- (3-chlorophenyl) -1,2,4-oxadiazol-3-yl] ethoxy} -4-methyl-4H-1,2,4- Triazol-3-yl) -1-methylpyridin-2 (1H) -one;
4- (5- {1- [5- (3-Chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine-2 (1H) -On;
4- (5-{[5- (3-Chlorophenyl) isoxazol-3-yl] methoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridin-2 (1H) -one ;
4- (5-{(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine- 2 (1H) -on;
4- (5-{(1R) -1- [5- (3-chlorophenyl) -1,2,4-oxadiazol-3-yl] ethoxy} -4-methyl-4H-1,2,4- Triazol-3-yl) pyridin-2 (1H) -one;
4- (5-{(1R) -1- [2- (3-chlorophenyl) -2H-tetrazol-5-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) Pyridin-2 (1H) -one;
5- (5-{(1R) -1- [2- (3-chlorophenyl) -2H-tetrazol-5-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) Pyridazine-3 (2H) -one;
5- (5-{(1R) -1- [5- (3-chlorophenyl) -1,2,4-oxadiazol-3-yl] ethoxy} -4-methyl-4H-1,2,4- Triazol-3-yl) pyridazin-3 (2H) -one;
5- (5-{(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridazine- 3 (2H) -on;
5- (4-Methyl-5-{(1R) -1- [2- (3-methylphenyl) -2H-tetrazol-5-yl] ethoxy} -4H-1,2,4-triazol-3-yl ) Pyridazin-3 (2H) -one; and
5- (4-Methyl-5-{(1R) -1- [5- (3-methylphenyl) isoxazol-3-yl] ethoxy} -4H-1,2,4-triazol-3-yl) pyridazine −3 (2H) −on,
A compound selected from the group consisting of: 活性成分としての請求項１〜１３のいずれか１項に記載の化合物を、薬理学的及び薬学的に許容しうる担体と共に含む、医薬組成物。   A pharmaceutical composition comprising the compound according to any one of claims 1 to 13 as an active ingredient together with a pharmacologically and pharmaceutically acceptable carrier. 5−m−トリル−イソオキサゾール−3−カルボン酸 メチルエステル;
5−m−トリル−イソオキサゾール−3−カルバルデヒド;
1−[5−(3−メチル−フェニル)−イソオキサゾール−3−イル]−エタノール;
1−[2−(3−クロロ−フェニル)−2H−テトラゾール−5−イル]−エタノン;
酢酸 (1R)−1−[2−(3−メチルフェニル)−2H−テトラゾール−5−イル]エチル;
酢酸 (1R)−1−[5−(3−メチルフェニル)イソオキサゾール−3−イル]エチル;
(1R)−1−[2−(3−メチルフェニル)−2H−テトラゾール−5−イル]エタノール;
(1R)−1−[5−(3−メチルフェニル)イソオキサゾール−3−イル]エタノール;
2−オキソ−1−(2−トリメチルシラニル−エトキシメチル)−1,2−ジヒドロ−ピリジン−4−カルボン酸 エチルエステル;
6−オキソ−1−(2−トリメチルシラニル−エトキシメチル)−1,6−ジヒドロ−ピリダジン−4−カルボン酸 エチルエステル;
2−オキソ−1−(2−トリメチルシラニル−エトキシメチル)−1,2−ジヒドロ−ピリジン−4−カルボン酸ヒドラジド;
6−オキソ−1−(2−トリメチルシラニル−エトキシメチル)−1,6−ジヒドロ−ピリダジン−4−カルボン酸ヒドラジド;
4−(5−メルカプト−4−メチル−4H−1,2,4−トリアゾール−3−イル)−1−｛[2−(トリメチルシリル)エトキシ]メチル｝ピリジン−2(1H)−オン;
4−[4−メチル−5−(メチルチオ)−4H−1,2,4−トリアゾール−3−イル]−1−｛[2−(トリメチルシリル)エトキシ]メチル｝ピリジン−2(1H)−オン;
2−ベンジルオキシ−4−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−ピリジン;
5−(2−メトキシピリジン−4−イル)−4−メチル−4H−[1,2,4]トリアゾール−3−チオール;
2−メトキシ−4−(4−メチル−5−メチルスルファニル−4H−[1,2,4]トリアゾール−3−イル)−ピリジン;
5−(4−メチル−5−メチルスルファニル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン;
4−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−メトキシピリジン;
4−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−1H−ピリジン−2−オン;
4−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−1−(2−トリメチルシラニル−エトキシメチル)−1H−ピリジン−2−オン;
5−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン;
2−ベンジルオキシ−4−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−ピリジン;
4−(5−メルカプト−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−1−メチル−1H−ピリジン−2−オン;
1−メチル−4−(4−メチル−5−メチルスルファニル−4H−[1,2,4]トリアゾール−3−イル)−1H−ピリジン−2−オン;
4−(5−メタンスルホニル−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−1−メチル−1H−ピリジン−2−オン;
2−ベンジルオキシ−4−(5−｛1−[5−(3−クロロ−フェニル)−イソオキサゾール−3
−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−ピリジン;
2−ベンジルオキシ−4−｛5−[5−(3−クロロ−フェニル)−イソオキサゾール−3−イルメトキシ]−4−メチル−4H−[1,2,4]トリアゾール−3−イル｝−ピリジン;
4−(5−｛(1R)−1−[2−(3−クロロフェニル)−2H−テトラゾール−5−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)−1−｛[2−(トリメチルシリル)エトキシ]メチル｝ピリジン−2(1H)−オン;
4−(5−｛(1R)−1−[5−(3−クロロフェニル)−1,2,4−オキサジアゾール−3−イル]エトキシ｝−4−メチル−4H−1,2,4−トリアゾール−3−イル)−1−｛[2−(トリメチルシリル)エトキシ]メチル｝ピリジン−2(1H)−オン;
2−ベンジルオキシ−4−(5−｛(R)−1−[5−(3−クロロ−フェニル)−イソオキサゾール−3−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−ピリジン;
5−(5−｛1−[5−(3−クロロ−フェニル)−[1,2,4]オキサジアゾール−3−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン;
5−(5−｛1−[5−(3−クロロ−フェニル)−イソオキサゾール−3−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン;
5−(5−｛1−[5−(3−メチル−フェニル)−イソオキサゾール−3−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン;
5−(5−｛1−[2−(3−メチル−フェニル)−2H−テトラゾール−5−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン;及び
5−(5−｛1−[2−(3−クロロ−フェニル)−2H−テトラゾール−5−イル]−エトキシ｝−4−メチル−4H−[1,2,4]トリアゾール−3−イル)−2−(2−トリメチルシラニル−エトキシメチル)−2H−ピリダジン−3−オン、
からなる群より選択される、化合物。 5-m-tolyl-isoxazole-3-carboxylic acid methyl ester;
5-m-tolyl-isoxazole-3-carbaldehyde;
1- [5- (3-methyl-phenyl) -isoxazol-3-yl] -ethanol;
1- [2- (3-chloro-phenyl) -2H-tetrazol-5-yl] -ethanone;
Acetic acid (1R) -1- [2- (3-methylphenyl) -2H-tetrazol-5-yl] ethyl;
Acetic acid (1R) -1- [5- (3-methylphenyl) isoxazol-3-yl] ethyl;
(1R) -1- [2- (3-methylphenyl) -2H-tetrazol-5-yl] ethanol;
(1R) -1- [5- (3-methylphenyl) isoxazol-3-yl] ethanol;
2-oxo-1- (2-trimethylsilanyl-ethoxymethyl) -1,2-dihydro-pyridine-4-carboxylic acid ethyl ester;
6-oxo-1- (2-trimethylsilanyl-ethoxymethyl) -1,6-dihydro-pyridazine-4-carboxylic acid ethyl ester;
2-oxo-1- (2-trimethylsilanyl-ethoxymethyl) -1,2-dihydro-pyridine-4-carboxylic acid hydrazide;
6-oxo-1- (2-trimethylsilanyl-ethoxymethyl) -1,6-dihydro-pyridazine-4-carboxylic acid hydrazide;
4- (5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl) -1-{[2- (trimethylsilyl) ethoxy] methyl} pyridin-2 (1H) -one;
4- [4-methyl-5- (methylthio) -4H-1,2,4-triazol-3-yl] -1-{[2- (trimethylsilyl) ethoxy] methyl} pyridin-2 (1H) -one;
2-benzyloxy-4- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -pyridine;
5- (2-methoxypyridin-4-yl) -4-methyl-4H- [1,2,4] triazole-3-thiol;
2-methoxy-4- (4-methyl-5-methylsulfanyl-4H- [1,2,4] triazol-3-yl) -pyridine;
5- (4-methyl-5-methylsulfanyl-4H- [1,2,4] triazol-3-yl) -2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one;
4- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -2-methoxypyridine;
4- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -1H-pyridin-2-one;
4- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -1- (2-trimethylsilanyl-ethoxymethyl) -1H-pyridin-2-one;
5- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one;
2-benzyloxy-4- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -pyridine;
4- (5-mercapto-4-methyl-4H- [1,2,4] triazol-3-yl) -1-methyl-1H-pyridin-2-one;
1-methyl-4- (4-methyl-5-methylsulfanyl-4H- [1,2,4] triazol-3-yl) -1H-pyridin-2-one;
4- (5-methanesulfonyl-4-methyl-4H- [1,2,4] triazol-3-yl) -1-methyl-1H-pyridin-2-one;
2-Benzyloxy-4- (5- {1- [5- (3-chloro-phenyl) -isoxazole-3
-Yl] -ethoxy} -4-methyl-4H- [1,2,4] triazol-3-yl) -pyridine;
2-Benzyloxy-4- {5- [5- (3-chloro-phenyl) -isoxazol-3-ylmethoxy] -4-methyl-4H- [1,2,4] triazol-3-yl} -pyridine ;
4- (5-{(1R) -1- [2- (3-chlorophenyl) -2H-tetrazol-5-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) -1-{[2- (trimethylsilyl) ethoxy] methyl} pyridin-2 (1H) -one;
4- (5-{(1R) -1- [5- (3-chlorophenyl) -1,2,4-oxadiazol-3-yl] ethoxy} -4-methyl-4H-1,2,4- Triazol-3-yl) -1-{[2- (trimethylsilyl) ethoxy] methyl} pyridin-2 (1H) -one;
2-Benzyloxy-4- (5-{(R) -1- [5- (3-chloro-phenyl) -isoxazol-3-yl] -ethoxy} -4-methyl-4H- [1,2, 4] triazol-3-yl) -pyridine;
5- (5- {1- [5- (3-Chloro-phenyl)-[1,2,4] oxadiazol-3-yl] -ethoxy} -4-methyl-4H- [1,2,4 ] Triazol-3-yl) -2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one;
5- (5- {1- [5- (3-chloro-phenyl) -isoxazol-3-yl] -ethoxy} -4-methyl-4H- [1,2,4] triazol-3-yl)- 2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one;
5- (5- {1- [5- (3-Methyl-phenyl) -isoxazol-3-yl] -ethoxy} -4-methyl-4H- [1,2,4] triazol-3-yl)- 2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one;
5- (5- {1- [2- (3-methyl-phenyl) -2H-tetrazol-5-yl] -ethoxy} -4-methyl-4H- [1,2,4] triazol-3-yl) -2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one; and
5- (5- {1- [2- (3-chloro-phenyl) -2H-tetrazol-5-yl] -ethoxy} -4-methyl-4H- [1,2,4] triazol-3-yl) -2- (2-trimethylsilanyl-ethoxymethyl) -2H-pyridazin-3-one,
A compound selected from the group consisting of: 一過性下部食道括約部弛緩の阻害のための医薬の製造のための、請求項１〜１３のいずれか１項に記載の化合物又はその薬学的に許容しうる塩若しくは光学異性体の使用。   Use of a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt or optical isomer thereof for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxation. . 胃食道逆流性疾患の処置又は予防のための医薬の製造のための、請求項１〜１３のいずれか１項に記載の化合物又はその薬学的に許容しうる塩若しくは光学異性体の使用。   Use of a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt or optical isomer thereof for the manufacture of a medicament for the treatment or prevention of gastroesophageal reflux disease. 疼痛の処置又は予防のための医薬の製造のための、請求項１〜１３のいずれか１項に記載の化合物又はその薬学的に許容しうる塩若しくは光学異性体の使用。   Use of a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt or optical isomer thereof for the manufacture of a medicament for the treatment or prevention of pain. 不安の処置又は予防のための医薬の製造のための、請求項１〜１３のいずれか１項に記載の化合物又はその薬学的に許容しうる塩若しくは光学異性体の使用。   Use of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt or optical isomer thereof, for the manufacture of a medicament for the treatment or prevention of anxiety. 過敏性腸症候群(IBS)の処置又は予防のための医薬の製造のための、請求項１〜１３のいずれか１項に記載の化合物又はその薬学的に許容しうる塩若しくは光学異性体の使用。   Use of a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt or optical isomer thereof for the manufacture of a medicament for the treatment or prevention of irritable bowel syndrome (IBS). .
JP2009530956A 2006-10-05 2007-09-25 mGluR5 regulator Pending JP2010505809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82832506P 2006-10-05 2006-10-05
PCT/IB2007/002784 WO2008041075A1 (en) 2006-10-05 2007-09-25 Mglur5 modulators

Publications (2)

Publication Number Publication Date
JP2010505809A JP2010505809A (en) 2010-02-25
JP2010505809A5 true JP2010505809A5 (en) 2010-11-11

Family

ID=39032082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530956A Pending JP2010505809A (en) 2006-10-05 2007-09-25 mGluR5 regulator

Country Status (21)

Country Link
US (1) US7772235B2 (en)
EP (1) EP2079730A1 (en)
JP (1) JP2010505809A (en)
KR (1) KR20090060328A (en)
CN (1) CN101547916A (en)
AR (1) AR062965A1 (en)
AU (1) AU2007303889B2 (en)
BR (1) BRPI0719155A2 (en)
CA (1) CA2665083A1 (en)
CL (1) CL2007002757A1 (en)
CO (1) CO6220935A2 (en)
IL (1) IL197722A0 (en)
MX (1) MX2009003227A (en)
NO (1) NO20091626L (en)
NZ (1) NZ575657A (en)
PE (1) PE20081378A1 (en)
RU (1) RU2439068C2 (en)
SA (1) SA07280518B1 (en)
TW (1) TW200821305A (en)
UY (1) UY30610A1 (en)
WO (1) WO2008041075A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922585A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Amino 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
US20100041706A1 (en) * 2008-08-12 2010-02-18 Astrazeneca Ab Compounds 501
MX2011001548A (en) * 2008-08-12 2011-03-15 Astrazeneca Ab A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine.
AU2009327566A1 (en) * 2008-12-18 2010-06-24 Astrazeneca Ab New process for the preparation of 1- [5- (3-chloro-phenyl) - isooxazol-3-yl] -ethanone and (R) -1- [5- (3-chloro-phenyl) - isooxazol-3-yl] -ethanol
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
MX2012003394A (en) * 2009-09-21 2012-08-15 Univ Vanderbilt O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators.
EP2632900A2 (en) * 2010-10-28 2013-09-04 Merck Sharp & Dohme Corp. Caprolactam mglur5 receptor modulators
JP2013544891A (en) 2010-12-08 2013-12-19 ヴァンダービルト ユニバーシティー Bicyclic pyrazole compounds as allosteric modulators of the mGLUR5 receptor
CA2821972A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
WO2018010163A1 (en) 2016-07-15 2018-01-18 泸州东方农化有限公司 Synthetic method for 1,2,4-triazole-3-thione compound and intermediate thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040847A1 (en) * 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-OXADIAZOLES AS METABOTROPIC GLUTAMATE RECEPTORS MODULATORS, FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0514296D0 (en) 2005-07-12 2005-08-17 Novartis Ag Organic compounds
AR058807A1 (en) * 2005-09-29 2008-02-27 Astrazeneca Ab 5- (PHENYLYSOXAZOLETOXI) -TRIAZOL-3-IL PIRIDINES REPLACED, FOR THE TREATMENT OF DISORDERS MEDIATED BY THE RECEIVER MGLUR5
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V

Similar Documents

Publication Publication Date Title
JP2010505809A5 (en)
RU2009111113A (en) MEDULATORS MGLUR5
JP2007523182A5 (en)
RU2008141509A (en) MGLUR5 MODULATORS 1
JP2007523181A5 (en)
AU2002349754B2 (en) Novel 1,2,4-triazole compound
JP2007523208A5 (en)
RU2352568C2 (en) [1,2,4]oxadiazoles (versions), methods of obtaining them, pharmaceutical composition and metod of inhibiting activation of metabotropic glutamate receptors - 5
TWI358409B (en) Heteroaryl substituted piperidine derivatives
JP2018535999A5 (en)
JP2007530690A5 (en)
JP2014517833A5 (en)
RU2006127572A (en) POLYHETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF A METABOTROPIC GLUTAMATE RECEPTOR
JP2006503009A5 (en)
JP2008513405A5 (en)
JP2015533157A5 (en)
JP2010515689A5 (en)
JP2007519717A5 (en)
JP2008513514A5 (en)
RU2006133909A (en) DERIVATIVES ASABICYCLO {3. 1. 0} HEXANES, APPLICABLE AS D3 DOPAMINE RECEPTOR MODULATORS D3
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
JP2007508346A5 (en)
JP2004511469A5 (en)
JP2009519965A5 (en)
JP2010513304A5 (en)